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Abstract
131I-MIBG therapy for neuroendocrine tumours may be dose limited. The common range of applied cumulative
activities is 10-40 GBq. We report the uneventful cumulative administration of 111 GBq (= 3 Ci)
131I-MIBG in a
patient with metastatic paraganglioma. Ten courses of
131I-MIBG therapy were given within six years,
accomplishing symptomatic, hormonal and tumour responses with no serious adverse effects. Chemotherapy with
cisplatin/vinblastine/dacarbazine was the final treatment modality with temporary control of disease, but eventually
the patient died of progression. The observed cumulative activity of
131I-MIBG represents the highest value
reported to our knowledge, and even though 12.6 GBq of
90Y-DOTATOC were added intermediately, no associated
relevant bone marrow, hepatic or other toxicity were observed. In an individual attempt to palliate metastatic
disease high cumulative activity alone should not preclude the patient from repeat treatment.
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Background
Targeted radiotherapy with
131I-metaiodobenzylguanidine
(
131I-MIBG) provides a generally well tolerated treatment
in chromaffin tumors; i.e. neuroblastoma, pheochromocy-
toma, and paraganglioma [1-4]. Hematotoxicity is the pri-
mary side effect depending on the administered activity,
metastatic bone marrow infiltration and other performed
treatment modalities as chemotherapy [5-7]. Treatment
protocols mostly use activities between 3.7 and 11.1 GBq
(100-300 mCi) per course [8,9]. Newer schedules use 14.8-
18.5 GBq (400-500 mCi) per treatment course and high-
dose concepts may incorporate an initial dose of > 22,2
GBq (600 mCi) supported by potential autologous stem-
cell rescue (ASCR) [10,11].
However, there is no existing recommendation for
repeat treatment or maximum cumulative activity. While
the common total administered activity per patient varies
between 10 and 40 GBq [9,12] occasional reports of
higher values up to 70 GBq do exist [10,13-16]. One
patient with metastatic pheochromocytoma was noted to
receive as much as 85.9 GBq (2321 mCi)
131I-MIBG [17].
We report on a case of metastatic paraganglioma
undergoing repetitive MIBG treatment during the
course of disease, resulting in an extraordinary high
cumulative activity of 3 Ci without any observed dose
limiting toxicity.
Case presentation
A 52-year-old female with a highly functional retroperito-
neal paraganglioma and previous tumorectomy was
referred for
131I-MIBG therapy in recurrent hepatic
metastatic disease. The patient suffered from hyperten-
sion, tachycardia and sweating.
131I-MIBG therapy was
initiated after confirmation of tumor uptake in a diagnos-
tic MIBG scan. The treatment was performed using 11.1
GBq (300 mCi)
131I-MIBG of high specific activity (GE
Healthcare, Amersham, Germany), given intravenously
by slow infusion. The minimum interval between two
courses of
131I-MIBG was eight weeks. Drugs known to
i n t e r f e r ew i t hM I B Gu p t a k ew e r ed i s c o n t i n u e db e f o r e
admission to treatment [18]. Thyroid uptake of free
radioiodine was blocked either by sodium perchlorate,
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any medium, provided the original work is properly cited.600 mg p.o. three times a day, administered for 3-6 weeks
(treatment cycle no.1-6) or by potassium iodide 100-200
mg per day plus levothyroxine 100 μg/d for 2-4 weeks
(treatment cycle no. 7-10). Blood pressure and heart rate
were monitored during
131I-MIBG infusion. Postthera-
peutic
131I-MIBG imaging was performed four to six and
eight to ten days after therapy, with whole body and pla-
nar scans using a dual head large-field-of-view gamma
camera (Picker Prism 2000 XP, Philips Medical Technol-
ogy, USA) with a high-energy collimator. Toxicity was
evaluated by extensive laboratory tests including com-
plete blood count and liver function tests. Treatment
response was assessed by CT and MRI, posttherapeutic
MIBG scintigraphy, 24-h urine sampling and monitoring
of catecholamine-related symptoms. For radiographic
tumour response the Response Evaluation Criteria of
Solid Tumors (RECIST) criteria were applied. The MIBG
scintigraphy was added for evaluation of bone metastases
(classically non-measurable disease in RECIST), i.e.
MIBG-positive bone metastases becoming MIBG-nega-
tive with accompanying sclerotic changes in CT were
interpreted as non-vital. Biochemical response was classi-
fied as CR (complete response) in complete normaliza-
tion and partial response (PR) in more than 50%
reduction of catecholamine levels. Symptomatic response
was categorized into complete (CR) and partial (PR) reso-
lution of functional symptoms. The first four MIBG
treatment courses-given within seven months-produced
a gradual and increasing symptomatic, biochemical and
radiographic tumour response corresponding with a par-
tial remission (PR). Figure 1 shows the first posttherapeu-
tic scan (a). Partial hepatectomy was performed and left
the patient with no detectable residual tumor. The com-
plete radiological and functional remission lasted almost
two years, when the patient experienced a relapse with
appearance of a few liver and lung metastases as well as a
retroperitoneal tumour lesion (Figure 1, b).
Four more courses of
131I-MIBG (cycle no. 5-8) were
subsequently given within one year. Following the sixth
131I-MIBG cycle the sodium perchlorate used for thyroid
blockade caused the patient fever, chills and a rash, and
oral iodine (100 mg per day) was used instead thereafter.
Again, a partial remission was achieved, but progression
occurred less than one year later with development of a
clinically predominant large metastatic liver lesion. Since
this centrally located lesion proved unresectable during
surgery, selective portal vein ligation of the affected liver
segments was performed. This procedure was followed
by two courses of Y-90-DOTATOC (performed at the
University Hospital Basel, Switzerland, with a total dose
of 12.6 GBq Y-90) after confirmation of tumour uptake
in somatostatin receptor scintigraphy using
111In-pente-
treotide. The initial response was good (PR), but shortly
later the patient experienced extensive multi-site disease
progression. The results of the reassessment at that time
with pre- and posttherapeutic scintigraphic imaging are
depicted in Figure 2, showing widespread metastases.
Since the concomitant scintigraphic somatostatin recep-
tor evaluation showed no additional tumour lesions com-
pared to the MIBG scan, there was no indication of
dedifferentiation (loss of MIBG-accumulating) of tumour
cells. At this advanced stage, only disease stabilization
and symptomatic relief were achieved by another 2
MIBG treatment cycles, with tumour progression occur-
ring after six months.
Then, the patient underwent chemotherapy with cyclo-
phosphamide, vincristine and dacarbazine (CVD regi-
men) with temporary control of disease, but eventually
died of progression. No dose limiting bone marrow toxi-
city was observed throughout and following chemother-
apy. It should be mentioned that stem cell support was
not available in this patient. Figure 3 gives an overview of
the various treatment applications over the course of
time including
131I-MIBG with the resulting cumulative
activity. The treatment response and hematologic toxicity
of all
131I-MIBG courses is given in Table 1. The only
observed adverse effect was a mild to moderate bone
marrow toxicity seen after some of the earlier courses of
MIBG therapy. It might have been caused by the perchlo-
rate medication used for thyroid blockade at therapy no.
1-6, as this agent is known to cause reversible leukopenia
in higher doses as been used in our case [19]. It is note-
worthy that no serious toxicity was observed throughout
the entire life-span although the high administered dose
met potential predisposing factors for liver failure such as
previous partial hepatectomy, selective portal vein liga-
tion and liver metastases.
Conclusions
We report the uncomplicated administration of 111
GBq (= 3 Ci) cumulative activity of
131I-MIBG without
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Figure 1 Post-therapeutic
131I-MIBG scans (anterior and
posterior view) of the 1
st (a) and 5
th (b) therapy showing the
well-accumulating metastases in the early to mid stages of the
disease.
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Figure 2
123I-MIBG (a) and
111In-pentetreotide (b) scans before MIBG therapy no. 9, followed by the post-therapeutic
131I-MIBG scan
(c): Later stage metastases to the lungs, liver, lymph nodes, soft tissue and bone, still displaying avid tracer uptake. The
111In-
pentetreotide scan shows no additional lesions compared to the MIBG scans.
Figure 3
131I-MIBG cycles with the resulting cumulative activity and other treatments over the course of time.
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potential of
131I-MIBG therapy in metastatic disease as
well as inter-individual dose-tolerance variability. This,
to our knowledge, represents the highest reported value
and compares to the outstanding cumulative activity of
85.9 GBq in one patient noted in a larger series before
[17]. In an individual attempt to palliate metastatic dis-
ease high cumulative activity alone should not preclude
the patient from repeat treatment.
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